ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Solasia Pharma KK

  • 176.00 JPY
  • +4.00
  • +2.33%
  • Japan
    Dec 14, 2018
  • Ticker
    TKS(4597)
  • Prev. close
    172
  • Market cap (JPY)
    18,005.24M
  • Market cap (USD)
    158.58M
  • Shares
    104.68M

Business Summary

Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. It expedites patient access to Western oncology and hematology therapies by developing products licensed from Western pharmaceutical and biotechnology companies. The company was founded by Bard Geesaman, John McDonald, and Koji Shinozaki in December 2006 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2017 JPYUSD
Revenue410.85M3.66M
Gross Profit410.32M3.65M
Operating income-1,009.68M-9.00M
Income before tax-1,016.28M-9.06M
Net income-1,007.48M-8.98M
EBITDA-1,009.15M-8.99M
Diluted EPS-12.24-0.10
Dividends Per Share00
Total Assets7,566.64M67.16M
Total liabilities1,358.08M12.05M
Total equity6,208.55M55.11M
Operating cash flow-911.39M-8.12M
Currency in JPYCurrency in USD

Historical Data

 Dec 2018Dec 2014Dec 2015Dec 2016Dec 2017
Revenue -- 11.95M 229.46M 501.31M 410.85M
Gross Profit -- 11.49M 228.52M 500.43M 410.32M
Operating income -- -702.01M -702.42M -462.47M -1,009.68M
Income before tax -- -701.98M -710.75M -494.63M -1,016.28M
Net income -- -677.03M -643.88M -474.43M -1,007.48M
EBITDA -- -701.54M -701.48M -461.59M -1,009.15M
Diluted EPS -- -26.90 -24.83 -18.46 -12.24
Dividends Per Share -- -- -- -- 0
Total Assets -- 2,204.82M 4,710.89M 4,451.44M 7,566.64M
Total liabilities -- 1,951.25M 3,712.05M 1,017.97M 1,358.08M
Total equity -- 253.55M 998.84M 3,433.46M 6,208.55M
Operating cash flow -- -631.81M -699.62M -464.98M -911.39M
 Dec 2018Dec 2014Dec 2015Dec 2016Dec 2017
Revenue -- 0.11M 1.89M 4.61M 3.66M
Gross Profit -- 0.10M 1.88M 4.60M 3.65M
Operating income -- -6.63M -5.80M -4.25M -9.00M
Income before tax -- -6.63M -5.87M -4.55M -9.06M
Net income -- -6.39M -5.31M -4.36M -8.98M
EBITDA -- -6.62M -5.79M -4.24M -8.99M
Diluted EPS -- -0.25 -0.20 -0.16 -0.10
Dividends Per Share -- -- -- -- 0
Total Assets -- 18.38M 39.16M 38.16M 67.16M
Total liabilities -- 16.27M 30.85M 8.72M 12.05M
Total equity -- 2.11M 8.30M 29.43M 55.11M
Operating cash flow -- -5.96M -5.77M -4.27M -8.12M

Valuation Measures

Dec 2017
PER--
ROA-16.76%
ROE-20.89%
Operating margin-245.75%
Profit margin-245.21%

Key executives

  • President & Representative Director: Yoshihiro Arai
  • CFO, Director & General Manager-Administration: Toshio Miyashita
  • Manager-Business Development: Koji Shinozaki
  • Manager-Accounting: Yasumitsu Shimada

Shareholders

  • ITOCHU Corp. (21.8%)
  • Meiji Holdings Co., Ltd. (3.6%)
  • Shinsei Corporate Investment Ltd. (2.7%)
  • Lee's Pharmaceutical Holdings Ltd. (2.1%)
  • Mitsui Sumitomo Insurance Venture Capital Co. Ltd. (1.1%)
  • Kyoto KK (0.9%)
  • ARAI YOSHIHIRO (0.1%)
  • MIYASHITA TOSHIO /SOLASIA/ (0.1%)

Contact Details

  • Website:http://www.solasia.co.jp
  • Address: Sumitomo Fudosan Shiba-Koen Tower 4F, 2-11-1 Shiba-koen, Tokyo, 105-0011, Japan
  • Phone: +81.3.5843.8045

Related Companies

    Competitors

    • Onxeo SA
    Last Updated on 14 Dec, 2018

    You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

    Subscribe to get unlimited access to all articles.

    Get unlimited access
    NAR site on phone, device, tablet

    {{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

    Stay ahead with our exclusives on Asia; the most dynamic market in the world.

    Benefit from in-depth journalism from trusted experts within Asia itself.

    Try 3 months for $9

    Offer ends September 30th

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media